Work

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-130290

Authors: Shebli Atrash, Myra Robinson, Manisha Bhutani, Jeffrey A. Zonder, Reed Friend, Barry Paul, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, Kelly Bumgarner, Sarah Norek, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani

Institutions: Levine Cancer Institute, University of Arkansas for Medical Sciences, The Barbara Ann Karmanos Cancer Institute, Multiple Myeloma Research Foundation

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2989489475

Cites:

Cited by: 1

Related to: 10